Virtual screening and in vitro experimental verification of LuxS inhibitors from natural products for Lactobacillus reuteri

Fanying Meng(Shanghai University), Jie Yu(Yunnan University of Traditional Chinese Medicine), Fan Zhang(Tufts University), Wen Gu(Chinese Center For Disease Control and Prevention), Min Yang(Kunming Third People's Hospital), Xue Li(South China Agricultural University), Yaqin Yang(Yunnan University), Qiuding Chen(Yunnan University)
Biomedicine & Pharmacotherapy
February 8, 2022
10.1016/j.biopha.2021.112521
Cited by 25

Related Papers

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
|Clinical Cancer Research|2019|53
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
|Cancer Biology & Therapy|2015|51
Potent Antitubulin Tumor Cell Cytotoxins Based on 3-Aroyl Indazoles
|Journal of Medicinal Chemistry|2007|50
SIRT1 Disruption in Human Fetal Hepatocytes Leads to Increased Accumulation of Glucose and Lipids
|PLoS ONE|2016|47